MUC16 and female reproductive organ cancer: CA125 cancer antigen 125, CHK1i cell cycle checkpoint kinase 1 inhibitor, GCIG Gynecologic Cancer InterGroup, HR hazard ratio, MV multivariate, OS overall survival, PFS progression-free survival, RECIST response evaluation criteria in solid tumors, UV univariate.